share_log

CVS Health | 8-K: Current report

CVS Health | 8-K: Current report

西维斯健康 | 8-K:重大事件
美股SEC公告 ·  10/18 05:50

Moomoo AI 已提取核心信息

On October 18, 2024, CVS Health Corporation announced a significant leadership change with the appointment of J. David Joyner as the new President and Chief Executive Officer, effective October 17, 2024. He succeeds Karen S. Lynch, who has stepped down from her role and resigned from the Board of Directors. Concurrently, Roger N. Farah has been appointed as Executive Chairman of the Board. Prior to his new role, Joyner served as the Executive Vice President and President of Pharmacy Services at CVS Health since January 2023 and has a long history with the company, including various executive roles. The announcement coincided with the release of preliminary third-quarter financial results for 2024, which included GAAP diluted EPS of $0.03 to $0.08 and Adjusted EPS of $1.05 to $1.10. The company...Show More
On October 18, 2024, CVS Health Corporation announced a significant leadership change with the appointment of J. David Joyner as the new President and Chief Executive Officer, effective October 17, 2024. He succeeds Karen S. Lynch, who has stepped down from her role and resigned from the Board of Directors. Concurrently, Roger N. Farah has been appointed as Executive Chairman of the Board. Prior to his new role, Joyner served as the Executive Vice President and President of Pharmacy Services at CVS Health since January 2023 and has a long history with the company, including various executive roles. The announcement coincided with the release of preliminary third-quarter financial results for 2024, which included GAAP diluted EPS of $0.03 to $0.08 and Adjusted EPS of $1.05 to $1.10. The company also disclosed charges related to premium deficiency reserves and a restructuring charge associated with store closures and cost reduction actions. Investors were advised that the previous guidance issued on August 7, 2024, should no longer be relied upon due to elevated medical cost pressures, and an update will be provided during the earnings call scheduled for November 6, 2024.
西维斯健康公司于2024年10月18日宣布进行了重大领导层变更,任命J. David Joyner为新任总裁兼首席执行官,任职时间为2024年10月17日。他接替了Karen S. Lynch,后者已经辞去职务并从董事会辞职。同时,Roger N. Farah被任命为董事会执行主席。在担任新职务之前,Joyner自2023年1月以来一直担任西维斯健康的执行副总裁兼药房服务总裁,并且在公司拥有着悠久的历史,包括担任各种高管职务。该公告与2024年第三季度初步财务业绩公布同时发布,其中包括按照普通会计准则摊薄后每股收益为0.03至0.08美元,调整后每股收益为1.05至1.10美元。公司还披露了与保费不足准备金有关的费用,以及与店铺关闭和成本削减措施相关的重组费用。投资者被告知,由于医疗成本上升压力,不应再参考2024年8月7日发布的先前指引,并将在2024年11月6日安排的业绩会议期间提供更新。
西维斯健康公司于2024年10月18日宣布进行了重大领导层变更,任命J. David Joyner为新任总裁兼首席执行官,任职时间为2024年10月17日。他接替了Karen S. Lynch,后者已经辞去职务并从董事会辞职。同时,Roger N. Farah被任命为董事会执行主席。在担任新职务之前,Joyner自2023年1月以来一直担任西维斯健康的执行副总裁兼药房服务总裁,并且在公司拥有着悠久的历史,包括担任各种高管职务。该公告与2024年第三季度初步财务业绩公布同时发布,其中包括按照普通会计准则摊薄后每股收益为0.03至0.08美元,调整后每股收益为1.05至1.10美元。公司还披露了与保费不足准备金有关的费用,以及与店铺关闭和成本削减措施相关的重组费用。投资者被告知,由于医疗成本上升压力,不应再参考2024年8月7日发布的先前指引,并将在2024年11月6日安排的业绩会议期间提供更新。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息